Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

BACKGROUND: Approximately 75% of objective responses to anti–programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted long after initial objective tumor regression despite continuous therapy. Mechanisms of immune escape in this...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Zaretsky, Jesse M., Garcia-Diaz, Angel, Shin, Daniel S., Escuin-Ordinas, Helena, Hugo, Willy, Hu-Lieskovan, Siwen, Torrejon, Davis Y., Abril-Rodriguez, Gabriel, Sandoval, Salemiz, Barthly, Lucas, Saco, Justin, Moreno, Blanca Homet, Mezzadra, Riccardo, Chmielowski, Bartosz, Ruchalski, Kathleen, Shintaku, I. Peter, Sanchez, Phillip J., Puig-Saus, Cristina, Cherry, Grace, Seja, Elizabeth, Kong, Xiangju, Pang, Jia, Berent-Maoz, Beata, Comin-Anduix, Begoña, Graeber, Thomas G., Tumeh, Paul C., Schumacher, Ton N.M., Lo, Roger S., Ribas, Antoni
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5007206/
https://ncbi.nlm.nih.gov/pubmed/27433843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1604958
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados